Apples and Oranges? Assessing Comparative Effectiveness and Comparative Value in the US and Other Countries  by Levy, Adrian R. & Garrison, Louis P.
Apples and Oranges? Assessing Comparative Effectiveness and
Comparative Value in the US and Other Countries
Adrian R. Levy, PhD,1,2 Louis P. Garrison Jr, PhD3
1Department of Community Health and Epidemiology, Dalhousie University, Halifax, NS, Canada; 2Oxford Outcomes,Vancouver, BC, Canada;
3School of Pharmacy, University of Washington, Seattle,WA, USA
Over the past 50 years, major advances have been made in both
the methods and application of health technology assessment
(HTA). For example, the Cochrane Collaboration and Evidence-
Based Medicine movement have provided systematized
approaches of critically reviewing the scientiﬁc literature. More
recently, new methods for making indirect comparisons are
appearing in the literature, which—when applied judiciously—
can be used to compare treatments in certain circumstances in
which no head-to-head study has been conducted. Although the
need for HTA was ﬁrst explicitly conceptualized and imple-
mented in the United States in the 1960s and 1970s, many other
countries followed suit. Indeed, in a number of countries, for
example, Australia, Canada, Sweden, and the United Kingdom,
rationalizing the use of new medical technologies became the
focus of many governmental and quasi-governmental health
agencies.
Over recent years, the United States has witnessed renewed
interest in HTA, including calls and legislation, for developing a
Centre for Comparative Effectiveness; however, there is still
much debate on the essential elements of this concept. The
ongoing discourse can beneﬁt from the HTA experiences of coun-
tries with well-established processes of HTA and the evolving
methodologies that facilitate unbiased assessment of comparative
effectiveness. This special issue showcases the presentations made
at the Apples and Oranges? Assessing Comparative Effectiveness
and Comparative Value in the US and Other Countries sympo-
sium held on May 15, 2009. The symposium, sponsored by
Oxford Outcomes, the National Pharmaceutical Council, and
Shire Pharmaceuticals, brought together a group of international
thought leaders who compared and contrasted the experiences of
countries that use formal HTA processes to review new medicines
and technologies and reviewed recent trends in comparative
effectiveness methodology.
The articles included in this supplement are edited versions of
the symposium presentations. The symposium was divided into
two sections. In the ﬁrst section, authors discussed the experience
with HTA in three jurisdictions:
• The United Kingdom, presented by Ron Akehurst, BSc,
Hon MFPHM, Professor of Health Economics. Dean and
Chair of Executive Board, School of Health and Related
Research, University of Shefﬁeld, Shefﬁeld, UK. The author
describes aspects of the Technology Assessment Program
that are underpinned by a ﬁxed health-care budget and
operated by the National Institute for Health and Clinical
Excellence (NICE). It is noted that the processes are under
great political and public scrutiny, are well recognized for
their robustness and transparency, and that despite the deci-
sions being sometimes highly contentious, NICE plays an
important role in facilitating public discussion of cost-
effectiveness thresholds of medical technologies. Moreover,
although difﬁcult to prove, NICE appraisal is believed to be
instrumental in improving various health outcomes in a
number of disease areas.
• Sweden, presented by Egon Jonsson PhD, Executive Direc-
tor and CEO, Institute of Health Economics, Alberta,
Canada. The author discusses the history of HTA in Sweden
and describes Sweden’s current wide-ranging policy-
orientated HTA process that covers the whole health-care
spectrum. HTA in Sweden involves multiple stakeholders
and comprehensively examines comparative effectiveness
within disease areas; for example, drug and alcohol abuse,
depression, obesity, and hypertension. The review results
provide an evidence base for best practices; however, it is
recognized that multiple barriers to the uptake of effective
technologies do exist.
• Canada, presented by Ron Goeree, BA MA, Associate Pro-
fessor, Department of Clinical Epidemiology & Biostatis-
tics, McMaster University & Director, Program for
Assessment of Technology in Health, Hamilton, ON,
Canada. The author describes the policy-orientated HTA
process of one of the largest health jurisdictions in Canada.
Here, technologies may undergo conditionally funded ﬁeld
evaluation (CFFE), also known as coverage with evidence
development. This approach facilitates the formulation of
evidence-based policy and informs budgetary decisions.
Examples of the monetary impact of CFFE indicate
improved value for money in various disease areas;
however, there are challenges associated with effectively
implementing CFFE that will require strong political will to
overcome.
In the second section, six methodological issues germane to com-
parative effectiveness research were addressed:
• Comparative assessment for medications and devices pre-
sented by Scott Ramsey, MD, PhD, Professor, University of
Washington, and Member, Fred Hutchinson Cancer
Research Center, Seattle, WA, USA. The author compares
the regulatory processes and costs associated with approval
of drugs with those for devices. The primary limitation of
the regulatory approval process for drugs is noted as the
lack of generalizability to “real world” patient populations;
and for devices, as the lack of requirement for randomized
trials.
• Contemporary challenges in deriving summary estimates of
comparative effectiveness using meta-analysis presented by
Ed Mills, MSc, PhD, LLM, Research Scientist, BC Centre
for Excellence in HIV/AIDS, Vancouver, BC, Canada and
University of Ottawa. The author discusses the use of
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meta-analysis for identifying signiﬁcant differences between
outcomes. As the success of meta-analysis is based on the
premise that the overall direction of effect will be relatively
consistent between clinical trials, it is proposed that that
broad pooling of data can then help resolve uncertainty that
may arise due to studies being underpowered, particularly
for sub-group analysis.
• Reﬂecting heterogeneity in patient beneﬁts: the role of sub-
group analysis with comparative effectiveness presented by
Mark Sculpher PhD, Professor of Health Economics and
Director of the Programme on Economic Evaluation and
Health Technology Assessment, University of York, Centre
for Health Economics, York, UK. The author discusses
methods for incorporating multifactorial heterogeneity to
capture sub-group beneﬁt across outcomes. The importance
of expressing health beneﬁt on a single scale is highlighted,
as well as the impact of medical history and patient prefer-
ence on absolute health beneﬁt.
• Transportability between countries of comparative effective-
ness presented by Andrew Briggs, BA, MSc, DPhil, Lindsay
Chair in Health Policy and Economic Evaluation, and Uni-
versity of Glasgow, Glasgow, UK. The author discusses the
merit and limitations associated with extrapolating com-
parative effectiveness data geographically. Examples are
used to illustrate methodological approaches that can be
applied to examine the signiﬁcance of differences in treat-
ment effects and the effect of treatment on quality of life in
different regions. It is noted that these effects appear to work
on different scales and that analyses must accommodate
multiple components to determine net clinical beneﬁt.
• Experimental and observational data and formulary listing
presented by Raulo Frear, Pharm D, Director, The Regence
Group. The author discusses the formulary decision-making
process by a large Health Insurance Group in the United
States. Emphasis is placed on the role of formulating key
research questions, adherence to a systematic approach to
critical appraisal, and transparency of the process.
Examples are used to illustrate the utility of the application
of critical appraisal of scientiﬁc evidence in informing for-
mulary decisions.
• Net Clinical Beneﬁt: the art and science of jointly estimating
beneﬁts and risks of medical treatment presented by Adrian
Towse, MA, MPhil, Director, Ofﬁce of Health Economics,
London. The author raises the issue of trade-offs between
positive and negative health effects, the utility of the QALY
as a risk–beneﬁt measure, and how patient willingness to
trade affects health outcomes for different sub-groups of
patients. It is noted that this ﬁeld is in its infancy and
whether or not weighting systems that account for positive
and negative health effects improve health-care decision-
making remains to be established.
The context for the symposium is the arguable assertion that
there is a widening gap between what consumers in health care
can expect and what can be delivered, and that there are a
number of contributing factors. First and foremost is the rising
cost of health care which, every year, continues to increase faster
than inﬂation and has led to concerns for payers worldwide. A
second major factor is the growing awareness of cost constraints
by payers worldwide; for example, in the United States, it has
now reached the point where the ﬁnancial viability of the health-
care system as a whole is being called into question. A third
factor, in many jurisdictions worldwide, is a growing expectation
from consumers as to what health care can deliver and how the
health-care system should help them maintain healthy lives.
Among other considerations, the ongoing introduction of
new health technologies signiﬁcantly contributes to rising health-
care costs. Health technology sales worldwide were estimated at
US$200 billion in 2008, with the United States’ share of the
world market accounting for about 45% [1]. Indeed, the medical
technology industry invests heavily in research and development,
leading to many new and effective health-care technologies
coming to market; the large majority of which come at an
increased cost. Not surprisingly, HTA and the comparative value
of new health technologies are of particular interest to payers of
today. That said, both Europe and the United States have a long
history of applying evidence-based health care. For example,
evidence-based practices were ﬁrst documented in Sweden in the
mid-1960s, whereas HTA per se essentially began in the 1970s in
response to the introduction of new, very expensive technologies,
the ﬁrst of which was the computerized tomography scanner (see
Jonsson, this issue), and evaluation of many other new technolo-
gies, including electronic fetal monitoring, mammography, and
magnetic resonance imaging followed. The United States saw one
of the ﬁrst agencies to assess the performance of new technolo-
gies, the Ofﬁce of Technology Assessment, established in 1972,
which existed until 1994, whereas HTA agencies were estab-
lished in Sweden, the UK, and Canada in 1987, 1999, and 2003,
respectively. The latest iteration of HTA in the United States has
been coined comparative effectiveness research. Gail Wilensky
(former Medicare head) has proposed that the United States
needs a body for comparative effectiveness research that is inde-
pendent of the federal government [2]. In an interesting contrast,
the United Kingdom’s NICE has had to become more responsive
to government through the introduction of single technology
assessments and through the consideration of a different thresh-
old of life-sustaining technologies, and so on. What we need to
ask now is the question posed by Sorensen and colleagues [3],
namely how could an independent HTA review body, such as
NICE, be instituted in the United States? And is this desirable and
feasible?
It is clear that answering these questions requires an under-
standing of what is meant by comparative effectiveness research.
The United States Institute of Medicine and the Congress initially
proposed that it was the relative value of different treatments,
particularly in terms of efﬁcacy or effectiveness, whereas the
Center for Medical Technology Policy and American College of
Physicians included cost-effectiveness in their deﬁnitions. One
organization outside of the United States—the Organization for
Economic Co-operation and Development—boldly suggested
that any center for comparative effectiveness in the United States
would likely only be undertaking cost-effectiveness assessments.
That vision contrasts with statements from Health and Human
Secretary Sebelius who emphasized that a center for comparative
effectiveness research would provide additional information to
patients and providers in order that they may make the best
decisions possible regarding their treatment options. Subsequent
to this symposium, the United States Institute of Medicine pub-
lished a working deﬁnition of comparative effectiveness research
(see Ramsey, this issue). This deﬁnition includes consumers, cli-
nicians, purchasers, and policymakers among the stakeholders,
suggesting that effectiveness, safety, and cost-effectiveness should
be considered. There are clearly a number of important debates
and questions about how to best assess the effectiveness of
medical technologies. First, whether or not to include costs and
budget impact is a very important decision. As health-care costs
steadily increase with the aging population, this has become the
topic of the day for many governments and health-care provid-
ers. Certainly, global economic events of the last year have
emphasized the immediacy of the issue, and the reality of hard
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choices in other realms suggests that this reality needs to be
embraced by the health-care sector.
Why Do We Need Comparative Effectiveness?
Regardless of the deﬁnition, it is important to understand why
we need comparative effectiveness research, and to acknowledge
that it is really because of an economic market failure. Informa-
tion itself is a “global public good,” with tremendous potential
impact. Economic theory predicts that a purely private market
system will tend to undersupply the socially optimal amount of
information because disclosure makes manufacturers vulnerable
to “information free-riders,” making it difﬁcult for manufactur-
ers to capture sufﬁcient value from their innovations. Although
the patent system works well to promote innovation and provide
information up to the point of launch (in the case of pharmaceu-
ticals), typically there are many unknowns regarding the effec-
tiveness and safety in the real world after products are on the
market. Indeed, there is a paucity of evidence on what is optimal
practice. This applies to medical technologies and services,
including drugs, devices, hospital distribution, and the speciali-
ties needed for optimal health-care implementation. Further-
more, although Canada (see Goeree, this issue) and Sweden (see
Jonsson, this issue) are taking steps to address the dearth of
follow-up data, once a technology is on the market, there are few
mechanisms for collecting and disseminating information on
how well a technology works. As a public good and because all
citizens of the world beneﬁt from reliable and valid information,
a large part of that responsibility should fall on central govern-
ments and it will require ﬁnding a way to ﬁnance ongoing data
collection from a global and public perspective.
Fixed health-care budgets, as applied in the United Kingdom,
are the characteristic that differentiates “extra-welfarism” from
“welfarism,” i.e., whether to rely more on social preferences (the
former) versus individual preferences. Setting a ﬁxed health-care
budget is a social choice that recognizes that resources are con-
strained and that hard choices must be made. In contrast, in
other jurisdictions there is no rigid budget; for example, in the
United States, this plus the abundance of subsidized health plans
have lead to health-care spending that is much higher than in
many other countries (approximately 16% of GDP in the United
States compared to between 8% and 12% in other Organization
for Economic Co-operation and Development countries).
An important question regarding comparative effectiveness in
countries that do not take costs into account is why is there so
little use of pharmacoeconomic information by payers. This is in
stark contrast to the way it is used in other jurisdictions such as
Australia, Canada (see Goeree, this issue), or the United
Kingdom (see Akehurst, this issue). One reason is that the ethical
underpinning of the latter health-care systems leans much more
toward “objective utilitarianism” and seeks to derive the greatest
societal value within a ﬁxed health budget. In contrast, the
United States’ leans more toward libertarianism and the rights of
individuals, with another reason being a lack of incentives to
make decisions that require explicit trade-offs. This is related to
many factors but most notably to tax subsidies for health insur-
ance. In the United States, this has been part of the recent
discussion on health-care reform, which may lead to pharmaco-
economics playing a greater role in health-care delivery in the
future.
Static and Dynamic Efﬁciency
Pharmacoeconomic cost-effectiveness analyses generally involve
calculating static efﬁciency in which the immediate price that the
payer has to pay is compared to the outcomes. This market price
of an innovative branded drugs is generally far above the short-
term marginal cost of making, marketing, and distributing the
product. Over the longer term, of course, the revenues generated
must reﬂect the ﬁnancing of the whole enterprise of discovery
through development to a marketable product. The limited
monopoly rights conferred under the patent system are the
primary tools used to ﬁnance research and development and can
be considered an issue of “dynamic efﬁciency.” To improve upon
this, we need to determine how to generate the optimal amount
of innovation over time by considering the link between the
reimbursement system and these long-term incentives, not only in
developed countries but in other countries as well. For example,
Brazil, Russia, India, and China (the “BRIC” countries) could
afford to contribute to the global research and development
effort. The challenge then becomes how to harness this global
demand to promote a greater rate of innovation. Although phar-
macoeconomists tend to focus on drugs, in industrialized coun-
tries they account for less than 20% of the health-care budget, so
what is really needed is to look at processes in the global health
care and R&D systems. Notably, as discussed by Egon Jonsson in
this issue, by applying a more comprehensive approach that
considers all treatments for a particular disease area, Sweden
may be considered among the most progressive countries under-
taking HTA.
Finally, although ideally technologies should be better evalu-
ated in terms of safety, phase IV trials are relatively rare and trials
powered for safety end points require such large sample sizes that
it is unrealistic that these will be carried out for all products. A
practical alternative is to monitor a risk–beneﬁt ratio that
involves ongoing data collection. As discussed by Scott Ramsey
in this issue, this poses a greater problem for devices than drugs
because of the challenges associated with evaluating devices
around blinding and “operator competence.” It is also worth
noting that a recent emerging conﬂict has arisen during current
debates about performance-based reimbursement for drugs
around operator competence, in which pharmaceutical compa-
nies are voicing concerns that physicians, as operators in this
sense, are out of their control, and may inﬂuence whether or not
a drug performs according to the manufacturers’ claims. Clearly,
many more intriguing questions will arise in the evolving debate
on comparative effectiveness research.
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